In recent years, several immune checkpoint inhibitors (ICIs) targeting the programmed death receptor-1 (PD-1) and programmed death ligand 1 (PD-L1) pathway have been tested for the treatment of HCC (2). The gene discussed is CD274; the disease is hepatocellular carcinoma.